Liraglutide and Renal Outcomes in Type 2 Diabetes - PubMed (original) (raw)
Randomized Controlled Trial
. 2017 Aug 31;377(9):839-848.
doi: 10.1056/NEJMoa1616011.
Collaborators, Affiliations
- PMID: 28854085
- DOI: 10.1056/NEJMoa1616011
Free article
Randomized Controlled Trial
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F E Mann et al. N Engl J Med. 2017.
Free article
Abstract
Background: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown.
Methods: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease. The risk of renal outcomes was determined with the use of time-to-event analyses with an intention-to-treat approach. Changes in the estimated glomerular filtration rate and albuminuria were also analyzed.
Results: A total of 9340 patients underwent randomization, and the median follow-up of the patients was 3.84 years. The renal outcome occurred in fewer participants in the liraglutide group than in the placebo group (268 of 4668 patients vs. 337 of 4672; hazard ratio, 0.78; 95% confidence interval [CI], 0.67 to 0.92; P=0.003). This result was driven primarily by the new onset of persistent macroalbuminuria, which occurred in fewer participants in the liraglutide group than in the placebo group (161 vs. 215 patients; hazard ratio, 0.74; 95% CI, 0.60 to 0.91; P=0.004). The rates of renal adverse events were similar in the liraglutide group and the placebo group (15.1 events and 16.5 events per 1000 patient-years), including the rate of acute kidney injury (7.1 and 6.2 events per 1000 patient-years, respectively).
Conclusions: This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048 .).
Comment in
- A New Chapter for Diabetic Kidney Disease.
de Boer IH. de Boer IH. N Engl J Med. 2017 Aug 31;377(9):885-887. doi: 10.1056/NEJMe1708949. N Engl J Med. 2017. PMID: 28854097 No abstract available. - Liraglutide and Renal Outcomes in Type 2 Diabetes.
Tonneijck L, van Raalte DH, Muskiet MHA. Tonneijck L, et al. N Engl J Med. 2017 Nov 30;377(22):2195. doi: 10.1056/NEJMc1713042. N Engl J Med. 2017. PMID: 29188961 No abstract available. - Liraglutide and Renal Outcomes in Type 2 Diabetes.
Gulli G. Gulli G. N Engl J Med. 2017 Nov 30;377(22):2195-6. doi: 10.1056/NEJMc1713042. N Engl J Med. 2017. PMID: 29188962 No abstract available. - Liraglutide and Renal Outcomes in Type 2 Diabetes.
Imprialos KP, Stavropoulos K, Doumas M. Imprialos KP, et al. N Engl J Med. 2017 Nov 30;377(22):2196. doi: 10.1056/NEJMc1713042. N Engl J Med. 2017. PMID: 29188967 No abstract available. - Liraglutide and Renal Outcomes in Type 2 Diabetes.
Thornton SN, Regnault V, Lacolley P. Thornton SN, et al. N Engl J Med. 2017 Nov 30;377(22):2196-7. doi: 10.1056/NEJMc1713042. N Engl J Med. 2017. PMID: 29188979 No abstract available. - Liraglutide and Renal Outcomes in Type 2 Diabetes.
de Boer IH. de Boer IH. N Engl J Med. 2017 Nov 30;377(22):2198. doi: 10.1056/NEJMc1713042. N Engl J Med. 2017. PMID: 29215858 No abstract available. - Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk.
Lipscombe LL. Lipscombe LL. Ann Intern Med. 2017 Dec 19;167(12):JC66. doi: 10.7326/ACPJC-2017-167-12-066. Ann Intern Med. 2017. PMID: 29255856 No abstract available.
Similar articles
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial. - Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Perkovic V, et al. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. N Engl J Med. 2019. PMID: 30990260 Clinical Trial. - Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Wanner C, et al. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14. N Engl J Med. 2016. PMID: 27299675 Clinical Trial. - Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes.
Guthrie R. Guthrie R. Postgrad Med. 2018 Mar;130(2):154-158. doi: 10.1080/00325481.2018.1430446. Epub 2018 Jan 25. Postgrad Med. 2018. PMID: 29350569 Review. - Cardiovascular Effects of Liraglutide.
Mikhail N. Mikhail N. Curr Hypertens Rev. 2019;15(1):64-69. doi: 10.2174/1573402114666180507152620. Curr Hypertens Rev. 2019. PMID: 29737256 Review.
Cited by
- Cardiovascular and diabetes outcomes among patients with obesity and type 2 diabetes after metabolic bariatric surgery or glucagon-like peptide 1 receptor agonist treatment.
Stenberg E, Ottosson J, Cao Y, Sundbom M, Näslund E. Stenberg E, et al. Br J Surg. 2024 Aug 30;111(9):znae221. doi: 10.1093/bjs/znae221. Br J Surg. 2024. PMID: 39235379 Free PMC article. - The Kidney in Obesity: Current Evidence, Perspectives and Controversies.
Kounatidis D, Vallianou NG, Stratigou T, Voukali M, Karampela I, Dalamaga M. Kounatidis D, et al. Curr Obes Rep. 2024 Aug 14. doi: 10.1007/s13679-024-00583-y. Online ahead of print. Curr Obes Rep. 2024. PMID: 39141201 Review. - A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes-2nd Edition (English version).
Bouchi R, Kondo T, Ohta Y, Goto A, Tanaka D, Satoh H, Yabe D, Nishimura R, Harada N, Kamiya H, Suzuki R, Yamauchi T; JDS Committee on Consensus Statement Development. Bouchi R, et al. Diabetol Int. 2024 Jul 11;15(3):327-345. doi: 10.1007/s13340-024-00723-8. eCollection 2024 Jul. Diabetol Int. 2024. PMID: 39101173 - Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial.
Tuttle KR, Bain SC, Bosch-Traberg H, Khunti K, Rasmussen S, Sokareva E, Cherney DZ. Tuttle KR, et al. Kidney Int Rep. 2024 May 22;9(7):2006-2015. doi: 10.1016/j.ekir.2024.04.028. eCollection 2024 Jul. Kidney Int Rep. 2024. PMID: 39081763 Free PMC article. - Myeloid-derived growth factor in diseases: structure, function and mechanisms.
Chen P, Huang X, Li W, Wen W, Cao Y, Li J, Huang Y, Hu Y. Chen P, et al. Mol Med. 2024 Jul 19;30(1):103. doi: 10.1186/s10020-024-00874-z. Mol Med. 2024. PMID: 39030488 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical